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Abstract
Background: Cerebrovascular lesions are a frequent finding in the elderly population. However, the impact of these
lesions on cognitive performance, the prevalence of vascular dementia, and the pathophysiology behind
characteristic in vivo imaging findings are subject to controversy. Moreover, there are no standardised criteria for
the neuropathological assessment of cerebrovascular disease or its related lesions in human post-mortem brains,
and conventional histological techniques may indeed be insufficient to fully reflect the consequences of
cerebrovascular disease.
Discussion: Here, we review and discuss both the neuropathological and in vivo imaging characteristics of
cerebrovascular disease, prevalence rates of vascular dementia, and clinico-pathological correlations. We also discuss
the frequent comorbidity of cerebrovascular pathology and Alzheimer’s disease pathology, as well as the difficult
and controversial issue of clinically differentiating between Alzheimer’s disease, vascular dementia and mixed
Alzheimer’s disease/vascular dementia. Finally, we consider additional novel approaches to complement and
enhance current post-mortem assessment of cerebral human tissue.
Conclusion: Elucidation of the pathophysiology of cerebrovascular disease, clarification of characteristic findings of
in vivo imaging and knowledge about the impact of combined pathologies are needed to improve the diagnostic
accuracy of clinical diagnoses.
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Background
Cerebrovascular disease (CVD) is highly prevalent in
brains of the elderly. However, its impact on cognition is
less clear and while prevalence rates of vascular demen-
tia (VaD) are high in clinical studies CVD is rarely found
to be the neuropathological correlate of clinical demen-
tia in post-mortem studies. In this review we highlight
some of the current problems in the diagnosis of CVD
and present novel approaches that may prove helpful to
elucidate the impact of CVD on cognitive performance.
Methods
This article was conceived at the 9th International Con-
gress of Vascular Dementia by participants of the Neuro-
pathology symposium following a discussion on current
problems regarding the clinical and pathological diagno-
sis of VaD and CVD.
Neuropathology of cerebrovascular disease
Degenerative cerebral vessel pathology
Three diseases of cerebral blood vessels mainly contrib-
ute to vascular cognitive impairment (VCI) and/or VaD:
(1) atherosclerosis (AS), (2) small vessel disease (SVD)
and (3) cerebral amyloid angiopathy (CAA). AS is a de-
generative vessel disorder affecting large to medium
sized cerebral arteries, most commonly the basilar ar-
tery and the circle of Willis [1], and results in the
formation of atherosclerotic plaques due to accumula-
tion of cholesterol-laden macrophages. Mature athero-
sclerotic plaques calcify, which may lead to narrowing
of the artery lumen, and they are prone to rupture,
resulting in subsequent thrombosis and potential
thromboembolism [2].
SVD encompasses three degenerative alterations of the
vessel walls of smaller cerebral arteries and arterioles.
The first, SVD-AS, has a similar pathogenesis to large
vessel AS but affects small intracerebral and leptomenin-
geal arteries (200–800 μm in diameter), which develop
microatheromas. The second, lipohyalinosis, affects
smaller arteries and arterioles (40–300 μm in diameter)
and is characterised by asymmetric fibrosis/hyalinosis as-
sociated with cholesterol-laden macrophage infiltration
that can occur with or without plasma protein leakage
as a result of blood–brain barrier (BBB) breakdown. The
third, arteriolosclerosis, presents as concentric hyaline
thickening of small arterioles (40–150 μm) that may lead
to stenosis of the blood vessel [3]. SVD initially mani-
fests as lipohyalinosis and arteriolosclerosis in vessels of
the basal ganglia, that is, the putamen and globus palli-
dus, and then in leptomeningeal arteries. By contrast,
SVD-AS develops in the leptomeningeal arteries, and af-
fects brain stem arterioles only in the end stages of SVD.
Cortical vessels on the other hand remain relatively free
of SVD pathology [4].
CAA is characterised by the deposition of amyloid-
beta (Aβ) (predominately Aβ-40) in the vessel walls of
leptomeningeal and cortical arteries, arterioles, capillar-
ies and, rarely, veins [5]. This results in the loss of
smooth muscle cells, disruption of vessel architecture
and, in very severe stages, Aβ depositions in the adjacent
neuropil (i.e. dyshoric changes). Topographically, CAA
usually presents in the neocortex, with more frequent
and severe deposition seen in the occipital region,
followed by the allocortex and cerebellum, and finally in
the basal ganglia, thalamus and white matter [6].
Cerebrovascular lesions
AS, SVD and CAA can all lead to various cerebrovascu-
lar lesions (CVLs), including infarcts, haemorrhages and
white matter lesions (WMLs). Ischaemic infarcts are typ-
ically observed after thrombotic or thromboembolic oc-
clusion of large to medium arteries, often as the result of
an AS plaque rupture. Haemorrhagic infarcts can occur
in infarcted regions in which the remaining vessels have
fragile vessel walls as a result of SVD or CAA, or they
may be caused by venous obstruction; less commonly,
haemorrhagic infarcts in the brain can be caused by col-
lateral blood influx into an infarcted area [7]. Large in-
farcts (>15 mm3) are frequently the result of thrombotic
(AS) or thromboembolic (AS, extracranial AS, cardio-
genic) occlusion of the vessel lumen [8]. Lacunar in-
farcts, that is, cavitating infarcts (5–15 mm3), are largely
confined to the white matter and subcortical grey matter,
and they are therefore primarily associated with SVD
[9]. Microinfarcts (<5 mm in diameter) can be present in
both the cortex and white matter, and they are associ-
ated with CAA and SVD respectively [3]. While cerebral
haemorrhages (>10 mm in diameter) can result from all
types of vessel disorders, those located in the subcortical
grey matter, brain stem and deep white matter are
strongly associated with SVD, whereas lobar haemor-
rhages are most commonly associated with CAA. Small
haemorrhages (<10 mm in diameter) and microbleeds
may histologically appear as extravasations of erythro-
cytes, but more frequently the only histological corre-
lates of microbleeds diagnosed by in vivo imaging are
haemosiderin-laden macrophages in the perivascular
space, which may or may not be the residue of a bleed.
In the cortex, small haemorrhages and microbleeds are
associated with CAA [10], whereas those located in the
white matter, subcortical grey matter and brain stem are
associated with SVD [11]. WMLs encompass structural
damage histologically characterised by white matter rar-
efaction, that is, demyelination and axonal loss, mild
astrocytosis, oedema and macrophage reaction [3]. Of
note, subcortical U-fibres are usually spared. WMLs are
generally assumed by clinicians and radiologists to be
the result of SVD-related chronic hypoperfusion and
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BBB alterations [12–14], although it is unclear if peri-
ventricular WMLs and deep WMLs share the same
pathogenesis (Fig. 1). In addition, severe neurodegenera-
tive pathology in the cortex has recently been suggested to
cause WMLs (see section ‘White matter hyperintensities’).
Pathological classifications of vascular dementia
CVLs can result in ‘pure’ VaD, that is, extensive vascular
lesions, without widespread neurodegenerative pathology
such as Alzheimer’s disease (AD) or Lewy body path-
ology, which explains the clinical dementia. VaD can be
classified into three major forms depending on lesion
distribution: multi-infarct dementia, strategic infarct
dementia or subcortical vascular encephalopathy. Multi-
infarct dementia is characterised by multiple lacunar
infarcts and microinfarcts, as well as small and/or large
infarcts in the cortex and subcortical regions. The total
amount of damaged cerebral tissue results in a signifi-
cant decrease in functional brain capacity, surpassing
the threshold for cognitive impairment. In contrast, stra-
tegic infarct dementia is the result of a single infarct in a
strategic region of the brain that results in significant
cognitive deficits, for example, a single lacunar or micro-
infarct in the hippocampus can lead to marked memory
impairment [15, 16]. Lastly, subcortical vascular enceph-
alopathy (synonymous with Binswanger’s disease) de-
scribes confluent severe demyelination and axonal loss
in the white matter with sparing of subcortical U-fibres
([13, 15, 16]; for review see [17]).
Comorbidity of cerebrovascular disease and Alzheimer’s
disease pathology
A large proportion of patients with dementia who have sig-
nificant CVLs also exhibit more severe concomitant AD
pathology [18], such as deposits of hyperphosphorylated
tau (HPτ) and Aβ, and thus fulfil the neuropathological
criteria for AD (Braak neurofibrillary tangle [NFT] stage V/
VI, Consortium to Establish a Registry for Alzheimer’s
Disease [CERAD] score C and Aβ phase 5 according to the
National Institute on Aging–Alzheimer’s Association
[NIA–AA] guidelines [19–22]). They are therefore classi-
fied as having mixed AD/VaD. The distinction between
AD, VaD and mixed AD/VaD remains controversial and
poses a difficult challenge (see section ‘Clinico-pathological
correlations and mismatch in VaD and mixed VaD/AD’).
Prevalence of vascular dementia
In clinical population-based series, the prevalence of
VaD/VCI averages 8–15.8 % (in Japan, 23.6–35 %) with
standardised incidence rates between 0.42 and 2.68 per
1000/year, increasing with age [23]. The range is broader
in clinical studies using convenience series from western
memory clinics, varying from 4.5 to 39 % [23]. However,
the prevalence rates of VaD/VCI are unlikely to be ac-
curate in any of these series because even the best clin-
ical diagnostic criteria show only moderate sensitivity
(approximately 50 %) and variable specificity (range 64–
98 %) [23, 24]. VaD in autopsy series also varies tremen-
dously, ranging from 0.03 to 58 % [23], and this variation
is partly due to the lack of internationally accepted con-
sensus criteria for the neuropathological diagnosis of
VaD. In elderly patients, the prevalence of ‘pure’ VaD
ranges from 5 to 78 %. In the oldest-old, that is,
≥90 years, the prevalence of pure VaD drops (to 4.5–
46.8 %) but that of mixed AD/VaD increases, reflecting a
constant age-related increase of neurodegenerative
changes. Rigorous population-based clinico-pathological
correlative studies addressing the prevalence of VaD are
few, but they are arguably more informative about the
actual prevalence of VaD/VCI. In population-based
clinico-pathological series, the prevalence of pure VaD
ranges from 2.4 to 23.7 %, and that of mixed AD/VaD
Fig. 1 Schematic diagram illustrating the three most commonly observed cerebrovascular diseases and their resulting cerebrovascular lesions
that may lead to specific types of vascular dementia
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from 4.1 to 21.6 % [25, 26]. The range is still wide and
this may reflect regional differences in managing cardio-
vascular risk factors and ethnic-related genetic variances.
In general terms, these studies show that the prevalence
of VaD/VCI is higher in developing countries and Japan.
For instance, in a clinico-pathological study from Brazil,
where cardiovascular risks are poorly managed, the
prevalence of pure VaD was 21.2 %, one of the highest
detected in population-based studies [26]. On the other
hand, in a retrospective hospital-based study in 1700
consecutive autopsy cases of elderly patients with de-
mentia in Vienna, Austria (mean age 84.3 ± 5.4 years;
90 % over 70 years), pure VaD was observed in 10.7 %,
decreasing between age 60 and 90+ from 15.0 to 8.7 %
[27]. VaD and VCI are potentially preventable diseases;
therefore, studies focusing on its prevalence, incidence
and risks factors in the different populations are essen-
tial to guide public policies.
Controversies in clinico-pathological correlation
of cerebrovascular disease
At present there are two fundamental issues regarding
the assessment and diagnosis of VaD. First, there are no
currently accepted neuropathological consensus criteria
regarding the assessment of VaD, VCI, cerebrovascular
pathology or related lesions [28]. Neuropathological as-
sessment of the post-mortem brain is required to reach
a definitive diagnosis and must be carried out in a stan-
dardised manner, applying reproducible methods and
following generally accepted consensus criteria [29].
Widely used consensus criteria for the pathological diag-
nosis of common neurodegenerative disease, such as AD
and Lewy body disease, have been available for some
time [19–21, 30–33]. However, despite several attempts
being made without major success [16, 34–36], generally
accepted neuropathological criteria for diagnosing VaD
are still unavailable. Second, general assumptions regard-
ing the underlying pathology of frequently observed in
vivo magnetic resonance imaging (MRI) findings might
not always be accurate. Neuroimaging is indeed an im-
portant tool in the clinical diagnosis of CVLs and
imaging-pathological correlative studies are aiming to
bridge the gap between in vivo imaging and post-
mortem neuropathology. However, general assumptions
regarding the underlying pathogenesis of common in
vivo MRI findings are not unequivocally corroborated by
neuropathological findings and this may result in inad-
equate clinical diagnosis and treatment.
Clinico-pathological correlations and mismatch in
vascular dementia and mixed Alzheimer’s disease/
vascular dementia
Various forms of cerebrovascular disorders may lead to
cognitive impairment and dementia in the elderly [17].
While pure VaD – most frequently caused by infarctions
– is rare, it is generally assumed that cerebrovascular
pathology contributes to the development of cognitive
impairment in other neurodegenerative diseases, in par-
ticular in mixed AD/VaD. Such mixed disorders are fre-
quently observed in the brains of elderly individuals and
their prevalence and severity increase with advancing
age [37]. In aged individuals, lacunes, microbleeds,
WMLs and microinfarcts have been associated with cog-
nitive decline, including reduced mental speed and im-
paired executive functions [38]. Cerebral SVD may
interact with pathophysiological processes in AD either
independently of each other or through additive or syn-
ergistic effects on cognitive decline [39, 40]. There are
several clinical classification criteria for VaD/VCI, such
as the NINDS-AIREN criteria, the State of California
Disease Diagnostic and Treatment Centers (ADDTC)
criteria, the International Classification of Diseases,
Tenth Edition ICD-10 criteria and the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V) criteria. They distinguish between the follow-
ing: possible VaD – clinical criteria of dementia with
focal clinical or imaging signs of one or more infarcts,
gait disorder, pseudobulbar palsy, personality and mood
changes; probable VaD – all signs of dementia, two or
more infarcts followed by dementia and imaging signs of
at least one extracerebellar infarct; and proven VaD – clin-
ically proven dementia and pathological demonstration of
multiple CVLs and mixed dementia. The diagnosis of
VaD/VCI is reflected by recent clinical criteria [41] that
are based on evidence of infarcts, white matter hyperin-
tensities (WMH) and microbleeds, using structural MRI.
Several autopsy studies have demonstrated that microin-
farcts are major risks for VCI; however, microinfarcts can
not be detected by 1.5 and 3.0 T MRI or naked eye exam-
ination, whereas they may be seen on novel high-
resolution 7.0 T MRI [42–45]. However, no accepted and
pathologically validated criteria for the diagnosis of VaD/
VCI are currently available [46]; therefore, the diagnostic
accuracy of possible VaD is still relatively poor, with an
average sensitivity of 0.49 (range 0.20–0.89) and an aver-
age specificity of 0.88 (range 0.64–0.98) [47, 48]. Cognitive
decline has been shown to be weighted on specific patho-
logical lesions in the following ranked order: NFT > Lewy
bodies > Aβ plaques >macroscopic infarcts [49]. In neuro-
pathologically defined mixed AD/VaD and SVD, the cog-
nitive impairment profile mirrors that seen in AD cases,
that is, all cognitive domains are equally impaired but
memory scores are lower than executive scores [50]. This
indicates that, regarding the combination of AD and SVD,
it is the AD pathology that has the greatest impact on the
severity and profile of cognitive impairment. Longitudinal,
clinical and neuropathological studies have previously il-
lustrated the impact of AD pathology in mixed AD/VaD,
McAleese et al. BMC Medicine  (2016) 14:129 Page 4 of 16
and demonstrate the usefulness of multivariate approaches
to understand clinico-pathological profiles, as well as
highlighting the current limitations to modelling and pre-
dicting cognitive decline and clinical profiles [49]. Never-
theless, the detection of the preclinical stages of cognitive
impairment and early AD changes became a reality with
the inception of amyloid PET tracers and various Aβ li-
gands, for example, Pittsburgh Imaging Compound B (PiB),
fluorbetapir and flutemetamol [51]. Several studies have
illustrated how amyloid PET imaging will improve differen-
tiation between AD and mixed AD/VaD cases of dementia.
Converging evidence suggests that cerebrovascular
and AD pathology exert an additive (and/or synergistic)
effect on cognitive impairment. Does CVD merely re-
duce the cognitive threshold needed for overt clinical
dementia in AD, or do both factors potentiate AD-
specific pathophysiological pathways? Recent neuroim-
aging studies in cognitively normal elderly people aged
70–90 years suggested that vascular and amyloid path-
ologies are at least partly independent predictors of cog-
nitive decline in the elderly, and that cognitive reserve
seems to offset the deterioration effect of both patholo-
gies on the cognitive trajectories [52].
Concomitant CVLs increase the risk and severity of
clinical dementia in elderly individuals meeting the
neuropathological criteria for AD [53–55]. However,
many studies emphasise additional pathogenesis in older
people without dementia, in particular CVLs, with, for
example, small or large cerebral infarcts, lacunar infarcts
and WMLs reported in 22 to almost 100 % of cases [48,
55–61]. Cerebral infarcts were seen in 21–48 % of se-
niors without dementia, with a higher frequency of large
infarcts [48, 55, 58, 60, 62–64] and CAA [55, 58].
Among 418 participants without dementia in the Reli-
gious Order Study (mean age 88.5 ± 5.3 years), 35 %
showed macroscopic infarcts; those without macroscopic
infarcts had microinfarcts (7.9 %), arteriosclerosis
(14.8 %) or both (5.7 %), with only 37.5 % being free of
CVLs [63]. In a study of 336 cognitively normal elderly
adults, cerebral microinfarcts were seen in 33 % and
high-level microinfarcts in 10 % [65]. In another study of
100 elderly participants without dementia (mean age
81.2 ± 5.4 years), CVLs including basal ganglia/deep
white matter lacunes were seen in 73 % and CAA in
39 %; only 9 % of these participants were free of CVLs
[66]. There were no correlations between CVLs and AD-
related pathology in this latter cohort, whereas others re-
ported an inverse relationship between Braak NFT stage
and CVLs in autopsy-proven AD [67, 68]. The profile of
AD and vascular changes becomes more complex with
increased cognitive impairment in older people without
dementia and these changes are likely to constitute a
major substrate for age-associated cognitive impairment,
suggesting a need for rigorous investigation of both
neurodegenerative and vascular risk factors in old age
[61]. However, the interactions in the pathophysiology
between vascular risk factors, CVD and AD pathology,
while plausible, are still unresolved.
In contrast to AD, less is known about the impact of
CVD in other common neurodegenerative diseases, such
as dementia with Lewy bodies (DLB) and frontotemporal
lobar degeneration (FTLD). Prevalence reports of CVD
in DLB are scarce, but autopsy studies reported a fre-
quency of 20.2–34.4 % [69, 70], which does not differ
significantly from controls [70]. In addition, an autopsy
study indicated that more advanced Lewy body path-
ology is less likely to show severe CVD, and therefore
suggested that cognitive impairment in DLB appears to
be independent of CVD [71]. With regards to the het-
erogeneous group of FTLD, data in relation to the preva-
lence and patho-mechanistic role of CVD are very
limited and contradictory. One autopsy study reported a
frequency of 5.2 % for FTLD-tau and 17.3 % for FTLD-
TDP-43 [69]. Some data support a role for SVD in
FTLD disease progression [72], while others could not
confirm this [69]. Therefore, further studies are neces-
sary to clarify the role of CVD in non-AD neurodegener-
ative diseases.
In conclusion, the co-occurrence of CVD and AD in
the elderly is very frequent [73]. There is evidence sug-
gesting that both lead, in an additive as well as an inde-
pendent fashion, to cognitive dysfunction. The
characteristic pattern of HPτ-related neurodegeneration
(i.e. Braak NFT stages) in AD corresponds to a pattern
of memory loss that spreads to other cognitive domains.
By contrast, the neuropsychological profile associated
with VaD shows considerable variation; for example, ex-
ecutive dysfunction often equals or may exceed memory
impairment in the SVD-subtype of VaD, but depending
on location and severity of CVL all possible types of
cognitive impairment may ensue. We anticipate that the
availability of comparable measures of AD and VaD
pathology from in vivo neuroimaging studies in the fu-
ture will replace dichotomous classifications of diseases
with more sophisticated modelling. However, as of today,
the best available models predict less than half of the
variance in cognitive performance [49].
White matter hyperintensities
WMLs histologically encompass structural damage of
the cerebral white matter as a result of white matter rar-
efaction [3]. They are visualised as WMHs on pre- and
post-mortem T2-weighted MRI, and they have been as-
sociated with a wide range of cognitive deficits [74].
Interestingly, WMHs are frequently seen in individuals
both with and without dementia, although WMHs seen
in AD are significantly more severe than the ones seen
in so-called normal ageing [75–77]. The pathogenesis of
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WMHs is generally thought to be associated with SVD
because vessel wall alterations may lead to chronic hypo-
perfusion of the surrounding white matter [35]. Al-
though WMHs are currently assumed to reflect SVD,
WMHs on T2-weighted MRI are a visualisation of white
matter abnormalities and cannot determine the under-
lying pathogenesis. Previous studies have suggested a
multifactorial aetiology of WMHs [78–82] inclusive of
SVD-related ischaemia, but also degenerative axonal loss
secondary to cortical AD pathology, that is, deposits of
HPτ and Aβ. The exact pathological mechanism of de-
generative axonal loss is still unclear, but it has been
suggested that axonal death occurs simultaneous to grey
matter atrophy or via calpain-mediated degradation, ac-
tivated by AD pathology-related axonal transport dys-
function [83, 84]. Evidence from neuroimaging has
shown region-specific white matter changes in patients
with AD, most frequently in the posterior deep white
matter [75, 85, 86] and corpus callosum [75], which have
been directly associated with AD-related cortical atrophy
[85, 86].
HPτ has been implicated as a principle instigator of
degenerative axonal loss in AD. An extensive quantita-
tive neuropathological study revealed that the burden of
cortical HPτ in the temporal and parietal lobes was a
predictor of WMH severity in AD [87], corroborating
previous studies reporting an association between higher
Braak NFT stage and increased WMH severity [77, 78,
88], and degenerative axonal loss in temporal [89] and
parietal [84] white matter when in proximity to high cor-
tical HPτ pathology burden. Furthermore, the combin-
ation of high cerebrospinal fluid (CSF) total-tau and
higher parietal WMH volume was shown to predict the
clinical conversion from mild cognitive impairment to
AD [89],further supporting an association between the
two pathologies. Although SVD-related ischaemic dam-
age has long been assumed to be the main factor for the
development of WMHs (for review see [90]), neuro-
pathological investigations of patients with AD with
severe WMH usually revealed only minimal SVD path-
ology [84, 89, 91]. However, in cases with minimal neo-
cortical HPτ pathology (Braak NFT stage 0–II), SVD was
found to be associated with WMH (Fig. 2) [92].
While theoretically both cortical HPτ pathology and
SVD may lead to the development of WMH, it ap-
pears that in neurodegenerative diseases such as AD,
WMHs are likely to be primarily associated with cor-
tical HPτ pathology. On the other hand, in cases
without dementia and in VaD cases, SVD seems to
play a role in the development of WMH, which may
relate to gliovascular abnormalities and BBB damage
[93]. The clarification of the underlying pathogenesis
of WMH and respective MRI characteristics is war-
ranted to allow for clear interpretation of white
matter neuroimaging and subsequent adequate man-
agement of patients.
Cerebral microbleeds
The term cerebral microbleeds describes the radiological
phenomenon of small, well-demarcated, hypointense,
round or ovoid lesions detected on T2*-weighted
gradient-recalled echo (T2*-GRE) and susceptibility-
weighted imaging (SWI) MRI sequences [10]. Micro-
bleeds create a ‘blooming’ effect on T2*-GRE/SWI, but
are generally difficult to see on T1-weighted or T2-
weighted sequences [10, 92]. Microbleeds have generated
interest as a marker of the haemorrhagic consequences
of SVD. Microbleeds are common in many different pa-
tient populations (healthy elderly, ischaemic stroke, in-
tracerebral haemorrhage [94, 95], AD [96, 97] and VCI
[98]). Of note, microbleeds are more prevalent in pa-
tients with recurrent stroke than in those with first-ever
stroke, and they tend to accumulate over time, indicating
a relationship with the progression and severity of cere-
brovascular pathology [94]. Microbleeds generate in-
creasingly common clinical dilemmas due to the
concern that they may be a marker of future intracere-
bral bleeding risk [99–104]. In a meta-analysis of 10 pro-
spective studies including 3067 patients with ischaemic
stroke or transient ischaemic attack, the presence of
microbleeds was associated with a high risk of intracere-
bral haemorrhage (pooled odds ratio 8.53), raising ques-
tions regarding the safety of antithrombotic drugs [105,
106]. Moreover, most available studies suggest that
microbleeds are associated with impairment of cognitive
function [107, 108], although whether they are directly
and independently implicated – or simply reflect more
severe SVD – remains uncertain.
Similar to other SVD markers, microbleeds appear to
represent a potential link between stroke, brain ageing,
dementia and AD [97, 109], but they have not yet re-
sulted in high-quality evidence-based recommendations
for stroke and dementia clinical practice nor emerged as
a valid surrogate marker for clinical trials in SVD, for ex-
ample, in intracerebral haemorrhage and VCI. This
might be due to the significant gap between the clearly
defined markers seen on MRI and their as-yet uncertain
pathological basis and pathophysiological mechanisms
[109–112]. It is consistently emphasised in the literature
that microbleeds are the MRI correlate of extravasation
of red blood cells from arterioles and capillaries dam-
aged by a primary haemorrhagic SVD process and,
therefore, are potentially strongly associated with haem-
orrhagic stroke risk. However, microbleeds are also asso-
ciated with increased subsequent ischaemic stroke risk
[113–116], highlighting that they are a marker of a CVD
that is simultaneously ischaemic and haemorrhagic, a
phenomenon sometimes termed mixed CVD [109, 117].
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Nonetheless, histopathological correlation studies sug-
gest that radiologically defined microbleeds generally
correlate with focal deposits of blood-breakdown prod-
ucts, predominantly haemosiderin-iron [110, 118]. MRI-
histopathological correlation has been underutilised
[119, 120], with a total of <70 microbleeds analysed in
just a small sample of patients [110–112], often detected
using relatively insensitive T2*-GRE sequences at 1.5 T
[118]. Technical challenges involved in correlating MRI
with histopathology for such small lesions with a wide-
spread distribution in the brain probably account for the
small number of brains with microbleeds that have been
analysed. Notwithstanding these limitations, when sys-
tematic neuropathological examination of SWI-visualised
microbleeds is undertaken, the underlying pathologic sub-
strates are actually rather variable, including not only focal
accumulations of blood-breakdown products, but also
(albeit much less commonly) microaneurysms, small
lacunes, vessel wall dissections or (pseudo-) microaneur-
ysms [112, 118, 121, 122].
Although most microbleed pathological correlation
studies emphasise blood leakage from nearby damaged
small vessels into the brain parenchyma as a mechanism,
it must not be assumed that a primary haemorrhagic
process fundamentally produces all microbleeds or that
the most severely affected vessels are the culprits. Alter-
native non-haemorrhagic mechanisms for microbleeds,
particularly if no tissue damage surrounds the vessel and
haemosiderin is limited to the perivascular space, in-
clude ischaemia-mediated iron store release by oli-
godendrocytes [123], phagocytosis of red blood cell
microemboli into the perivascular space (termed angio-
phagy) [121, 124], or even haemorrhagic transformation
of small microinfarcts (Fig. 3) [125].
Fig. 2 A series of images for three separate cases indicating normal-appearing white matter and the similarity of white matter changes with differing
pathogenesis in the deep white matter of the parietal lobe (Brodman area 39/40), as seen on both T2-weighted magnetic resonance imaging (MRI)
and on histology. (A–Aiv) Normal-aged control brain with no obvious white matter changes or small vessel disease (SVD), and no Alzheimer’s disease
(AD)-related pathology: (A) post-mortem T2-weighted MRI scan of normal-appearing white matter; (Ai, Aii) corresponding histological magnified image
of normal-appearing white matter and a normal white matter artery (Aii); (Aiv) overlying cortex with no hyperphosphorylated tau (HPτ) pathology.
(B–Biv) Normal-aged case that exhibited severe white matter hyperintensities (WMHs)/lesions with SVD but no AD pathology: (B) post-mortem T2-
weighted MRI scan indicating confluent WMH; (Bi) corresponding histological magnified image of white matter lesion indicated by widespread pallor
of the central white matter with typical sparing of the subcortical U-fibres (arrow); (Bii) higher magnification of white matter lesion exhibiting severe
rarefaction, that is, myelin and axonal loss; (Biii) white matter arterioles from white matter lesion area exhibiting arteriolosclerosis with hyalinisation
(arrows) of vessel walls; (Biv) overlying cortex with no HPτ pathology. In this case, one may speculate SVD-related hypoperfusion was the primary cause
of white matter changes. (C–Civ) AD brain exhibiting severe WMHs/lesions and no obvious SVD: (C) post-mortem T2-weighted MRI scan indicating
confluent white WMH; (Ci) white matter lesion with severe white matter pallor; (Cii) magnified image of severe white matter rarefaction; (Ciii) white
matter arteriole with enlarged perivascular space but no SVD-related fibrosis or hyalinisation; (Civ, overlying parietal cortex exhibiting severe HPτ
pathology. In this case, one may speculate white matter changes were the result of degenerative myelin and axonal loss as a result of grey matter
atrophy in the overlying cortex or via protease-mediated degradation, activated by AD pathology-related axonal transport dysfunction. MRI scans
captured in sagittal plane. Microphotoimages captured from serial sections. Histological stain Luxol fast blue was used for images Ai–ii, Bi–ii and Ci–ii;
hematoxylin and eosin stain was used for Aiii, Biii and Ciii. Immunohistochemistry with the AT8 antibody was performed in Aiv, Biv and Civ. Scale bars
represent 1000 μm in images A, B and C and 20 μm in images Ai–iii, Bi–iii and Ci–iii
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It is widely accepted that, by analogy with spontan-
eous intracerebral haemorrhage, the pathological pro-
cesses underlying microbleeds differ according to
their location in the brain, with CAA being the most
notable correlate of exclusively lobar microbleeds
(most often in the occipital and posterior temporo-
parietal regions), while ‘hypertensive arteriopathy’
(including a spectrum of neuropathological processes
affecting deep perforating vessels such as AS and
lipohyalinosis) is strongly associated with predomin-
antly deep microbleeds. The majority of data to date
support this hypothesis, but much of the evidence is
indirect and largely based on clinical and imaging
studies [10, 112, 126–130], rather than extensive
direct morphological-pathological analyses [131]. A
recent neuropathological study found no direct topo-
graphical association between CAA presence or sever-
ity and microbleeds (defined only pathologically as
haemosiderin-laden macrophages in any brain region)
[132]. Whether these microscopic lesions have the
same biological significance and underlying mecha-
nisms as radiologically defined microbleeds is not
clear [120]. Further exploration of the neuropatho-
logical basis of microbleeds will be a key step in
clarifying their mechanisms and nature. Along with
well-designed observational clinical studies, this
greater understanding should allow microbleeds to be-
come useful in clinical management decisions [133].
Until then, the main question of whether a radiologic-
ally defined microbleed is always a true microbleed or
whether it may also represent haemosiderin deposits,
which in turn may or may not stem from a micro-
bleeding event, remains unanswered.
Additional novel approaches to complement and
enhance current post-mortem assessment of
cerebral human tissue
With regards to CVL, novel applications of neuroimag-
ing and biochemical methods, as well as additional in-
vestigation of neuroinflammation, have been suggested
for the assessment of human post-mortem brains. Al-
though these methods are beyond the scope of basic
routine diagnostic procedures, the addition of such novel
techniques may help to further elucidate the impact of
CVD on cognitive performance.
Post-mortem neuroimaging
Post-mortem MRI provides a technique to complement
research, and routine, neuropathological investigations,
providing visualisation of cerebral lesions for radiological
assessment or a precise location for histological examin-
ation. Direct comparison studies have found that gross
MRI lesions are almost identical between human in vivo
and post-mortem MRI scans [134], with limited effects on
MRI characteristics due to the fixation process [135, 136].
A variety of post-mortem MRI approaches have been
implemented, including scanning of fixed whole
brains or hemispheres [77, 134, 135, 137–140], cor-
onal brain slices [141, 142], un-fixed whole brains
[134] and brains in situ [143].
Frequently, post-mortem MRI is used for the detection
and assessment of WMH. A recent study investigated the
reliability of post-mortem MRI to assess WMH of the
deep white matter: 4.7 T MRI scanning was carried out on
40 post-mortem fixed right brain hemispheres, and
WMHs in the deep white matter were rated according to
the Age-Related White Matter Change Scale (ARWMC)
Fig. 3 Magnetic resonance imaging (MRI) and histological sections of cerebral tissue exhibiting microhaemorrhages. (A) Radiological
characteristics of microhaemorrhages inclusive of small, well-demarcated hypointense ovoid lesions (arrow). (B–Ci) Images from an 81-year-old
man with dementia and severe cerebral amyloid angiopathy on pathology: (B) post-mortem 7 T MRI scan of hypointense ovoid lesion (arrow); (C)
magnified image of cortical microhaemorrhage; (Ci) increased magnified image of cortical microhaemorrhage – brown deposits are haemosiderin
(arrow) and yellow deposit is haematoidin (arrow head), indicating the microhaemorrhage is subacute. Histological stain hematoxylin and eosin
used on images C and Ci. Scale bars represent 1000 μm in image C, and 100 μm in image Ci. Images prepared by Dr S. van Veluw
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[144] and compared to scores from a thorough histo-
logical assessment (based on approximately 1200 sec-
tions). The study revealed no significant differences
between the post-mortem MRI WMH scores and histo-
logical assessments, regardless of the severity of the deep
white matter changes, demonstrating that post-mortem
MRI is a reliable measure of WMH that can be utilised to
complement neuropathological assessment of white mat-
ter changes. Of note, routine histological assessment based
on five histological sections per brain failed to reliably re-
flect thorough histological assessment.
Cortical microinfarcts (CMI) are another common le-
sion found in ageing and dementia, and are considered
the ‘invisible lesions’ in clinical–radiological correlation
studies [145], visible only upon microscopic examin-
ation. Developments in high-resolution 7.0 T MRI have
allowed for the detection of CMI in vivo [43]. This ap-
proach was utilised and established for the post-mortem
detection of several types of CMI by De Reuck and col-
leagues [45]; fixed coronal slices from 175 demented and
non-demented brains underwent a 7.0 T MRI, and mean
CMI and cerebral CMI loads were determined and com-
pared to the histological examination, revealing no stat-
istical differences between the two assessments.
Post-mortem MRI has also proved a valuable tool in
investigating the pathomechanisms of ischaemic stroke
in the human brain. This is of major potential import-
ance because many therapeutic interventions that have
proven successful in animal stroke models have not yet
been verified in human clinical trials (excluding thromb-
olysis and hypothermia). Developments in autoradiog-
raphy of intact human brain sections have allowed for
the visualisation of the ischaemic core by creating a ‘po-
tassium map’; a method which identifies the ischaemic
core by utilising the disruption of ion homeostasis and
subsequent efflux of water. This method allows for the
essential targeted tissue sampling of the ischaemic core
to facilitate quantitative measurements of tissue compo-
nents. The method for human brain sections, as de-
scribed by Csiba and colleagues [146], is reliant upon
post-mortem MRI (T1 and T2 weighted) to localise the
ischaemic lesions and serve as a gold standard compari-
son to the potassium map. Of note, in vivo MRI imaging
is not appropriate due to the possibility of new focal is-
chaemic lesions developing. Following post-mortem
MRI, the brain is frozen and the region of interest, that
is, the brain infarct with the perifocal brain tissue, is
cryosectioned using a heavy-duty microtome (LKB 2250
PMV Cryo-microtome; potentionally the entire hemi-
sphere can be cut and examined). The potassium map
method can be used to identify the necrotic core, pen-
umbra and perilesional brain on the cryosections [147],
with specific samples removed via a micropunch tech-
nique [148], allowing for subsequent analysis of water
content, proteomics and genetics. Although this com-
bined methodology of post-mortem MRI and potassium
mapping is beyond the scope of the routine diagnostic
work-up, it is unparalleled in providing targeted tissue
sampling for the post-mortem examination of an ischae-
mic brain in the research setting.
Biochemical assessment
While clinical, neuroimaging and pathological assess-
ment remain the main approaches for assessing vascular
lesions and their association with cognitive impairment
and other neurological disturbances, post-mortem bio-
chemistry provides additional insights into vascular
function [149] Biochemical assays enable us to measure
and investigate the mechanisms of vascular dysfunction,
including the activity and level of enzymes and proteins
that mediate changes in vascular calibre, permeability
and adhesion; cell migration; and vascular maintenance
and regeneration. They also allow the measurement of
structural protein levels, providing quantitative data on a
wide range of vascular and parenchymal cells and extra-
cellular constituents.
Advantages of including biochemical measurements
(in addition to more conventional morphological assess-
ments) include the fact that they are more sensitive for
the detection of hypoperfusion, they facilitate more rep-
resentative sampling (e.g. up to 0.5 ml of tissue in a sin-
gle homogenate compared with ~5 μl of tissue in a
paraffin section) and they yield objective continuous
data rather than subjective ordinal scores. Biochemical
approaches were recently used to gain some understand-
ing of the pathogenesis of cerebral hypoperfusion in
VaD, AD and DLB. Measurement of the levels of myelin
proteins with long half-lives but differential susceptibility
to hypoperfusion confirmed a significant reduction in
the perfusion of the cerebral cortex and white matter in
VaD [39, 150]. This was evidenced by a decline in the ra-
tio of myelin-associated glycoprotein (MAG) to proteoli-
pid protein 1 (PLP1). Whereas PLP1 is distributed
throughout the myelin sheath, MAG is located in the
adaxonal loop of myelin, the first part of the myelin
sheath to degenerate when the blood supply is inad-
equate to meet the energy requirements of the oligo-
dendrocyte (Fig. 4). Biochemical analysis confirmed the
significant decline in perfusion of the cerebral cortex in
AD as well as VaD [151]. A lower MAG to PLP1 ratio
was demonstrable in early AD (Braak NFT stages III and
IV) in the precuneus (the first region of the cortex to be
affected by a decline in blood flow in AD), indicating
that perfusion is inadequate to meet metabolic demand,
rather than that hypoperfusion is simply a reflection of
reduced metabolic activity [149]. The hypoperfusion in
AD could not be attributed to SVD or CAA, with which
there was no significant association. However, the
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severity of hypoperfusion was associated with a marked
increase in the concentration of the vasoconstrictor
endothelin-1 (EDN1) in the cerebral cortex in AD. A
correlation between the level of EDN1 and that of the
peptide Aβ42 was also demonstrated, suggesting that it
is the accumulation of Aβ42, which upregulates neur-
onal production of EDN1 by endothelin-converting
enzyme-2 [152], that drives the production of EDN1. In
contrast, the level of EDN1 did not correlate with that of
Aβ40, which upregulates endothelial production of
EDN1 by endothelin-converting enzyme-1 [153, 154]).
In the cerebral white matter, the main abnormality as-
sociated with hypoperfusion in both VaD and AD has
been demonstrated to be non-amyloid SVD [39]. The
concentration of EDN-1 in the white matter was found
to be reduced in AD, as was that of another vasocon-
strictor, angiotensin II, and the activity of angiotensin-
converting enzyme, the enzyme responsible for angio-
tensin II production [149]; these are likely to be adaptive
responses to reduced perfusion. However, perfusion of
the white matter (as measured by the MAG to PLP1 ra-
tio) has been shown to fall with increasing EDN-1 in the
overlying cortex, suggesting that vasoconstriction of per-
forating arterioles within the cortex probably contributes
to hypoperfusion of the underlying white matter in AD.
Additionally, the concentration of von Willebrand fac-
tor (VWF) in brain tissue is directly related to the dens-
ity of microvessels [151, 155]. Measurement of VWF has
several advantages over quantitative immunohistochemi-
cal methods of assessing microvessel density: the sample
size can be much larger (a 0.5 ml homogenate contains ∼
106-fold greater volume of tissue than a typical paraffin
section) and the same homogenate can be used to meas-
ure a wide range of related molecules, allowing direct
comparison between microvessel density and perfusion,
vascular function, and molecules responsible for regula-
tion of vascular growth, tone and permeability. This ap-
proach was used to assess possible causes of occipital
hypoperfusion in DLB and demonstrated significant
reduction in the level of VWF in the occipital cortex (a
region known to be hypoperfused in DLB) but not the
midfrontal cortex or thalamus [155]. Furthermore,
reduction of VWF correlated with a loss of MAG (a
marker of hypoperfusion, as noted above), as well as re-
duced levels of vascular endothelial growth factor
(VEGF), which is needed to maintain the vasculature.
Finally, reduced VEGF was revealed to be related to the
level of α-synuclein, not only in the post-mortem human
brain tissue but also in neuronal cell lines engineered to
over-express wild-type α-synuclein, suggesting that α-
synuclein may down regulate production of VEGF,
affecting maintenance of the microvasculature and of
cerebral perfusion.
These few examples illustrate the potential of post-
mortem biochemical analyses of brain tissue as a means
to measure vascular function and to investigate the
pathogenesis of vascular dysfunction.
Neuroinflammation – a contributor to vascular
dementia?
Aside from the hallmark pathological lesions, there is
evidence to suggest a role for immunological and inflam-
matory mechanisms in the pathophysiology of VaD/VCI.
Neuroinflammation encompasses local endothelial
activation, leading to the extravasation of fluid (and,
sometimes, cells) via a dysfunctional BBB, resulting in
oedema and tissue damage in the surrounding paren-
chyma and eventually leading to the activation of peri-
vascular macrophages, microglia and other glial subtypes
(Fig. 5a, b) [156–158].
Clinical studies in patients with symptomatic SVD
[159, 160] or WMH [161–163] found elevated levels of
circulating biomarkers of endothelial activation, that is,
Fig. 4 Schematic illustration of the distribution of myelin-associated
glycoprotein (MAG; pink dots) and proteolipid protein 1 (PLP1; green
dots) in the myelin sheath. When the supply of oxygen and glucose
is insufficient to meet the metabolic needs of the oligodendrocyte,
as occurs in hypoperfusion, the first part of the cell to degenerate
is the adaxonal loop of myelin – the part of the oligodendrocyte
that is furthest away from the cell body (so-called dying back
oligodendrogliopathy). Because MAG is restricted to the adaxonal
loop of myelin whereas PLP1 is widely distributed throughout the
myelin sheath, hypoperfusion leads to greater loss of MAG than
PLP1. In contrast, degeneration of nerve fibres causes loss of both
MAG and PLP1. The severity of ante mortem hypoperfusion can be
assessed by measuring the ratio of MAG to PLP1. Illustration from
[175] with permission from Prof. S. Love
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ICAM1, soluble thrombomodulin, interleukin-6 (IL-6)
and PAI-1. This suggests that endothelial activation, and
a possible inflammatory process, might contribute to
SVD and to cognitive decline. A neuropathological study
by Giwa and colleagues assessed endothelial activation
in small perforating arteries in cases with moderate-
severe SVD, and with minimal AD pathology (Braak
NFT stage 0–II, and insufficient neuritic plaque path-
ology to meet CERAD criteria for AD). They found that
endothelia were rarely immunoreactive for ICAM1 or
IL-6; however, levels of luminal thrombomodulin (deple-
tion of which is a hallmark of activated endothelium)
were more pronounced, especially in individual vessels
with severe high sclerotic index (Fig. 5c) [164]. The
study concluded that local endothelial activation is not a
feature of the arteriolosclerosis form of SVD, which is in
agreement with evidence from a previous study of brain
lysates demonstrating attenuation of inflammatory medi-
ators (MCP-1 and IL-6) in individuals with VaD and
mixed dementia, relative to aged control subjects [165].
While BBB dysfunction is often claimed to be part of
SVD pathology, neuropathology studies show no conclu-
sive association of BBB markers (fibrinogen, IgG, albu-
min; Fig. 5d) with SVD. Some neuropathology reports
found a positive association between SVD severity and
extravascular plasma proteins [166, 167] while others
did not [139, 168, 169]. In subcortical white matter, fi-
brinogen labelling was associated with clinical dementia
diagnosis in an AD-free cohort where dementia was
likely to be primarily VaD [169]. Observationally, little
evidence of leukocyte infiltration has been associated
with SVD. Microglia have been shown to be significantly
higher in number in the brains of persons with VaD and
widespread WMH [79, 170, 171]. Activated microglia
(CD68+) are strongly associated with WMLs (Fig. 5e, f )
[79, 142].
Elucidation of the role of neuroinflammation in the
pathogenesis and pathophysiology of SVD will enable
the evaluation of immunotherapies as potential thera-
peutic options for prevention or treatment of VCI/VaD.
Conclusion and outlook
It becomes increasingly clear that standardised neuropatho-
logical criteria for the assessment of CVD in human post-
mortem brains are needed [172]. In order to establish such
criteria, Brains for Dementia Research initiated a UK multi-
centre collaborative study to formulate evidenced-based
Vascular Cognitive Impairment Neuropathology Guidelines
(VCING) for post-mortem assessment of CVD of relevance
to VCI. Nine neuropathologists undertook a Delphi method
series of surveys to agree on a neuropathological sampling
protocol and scoring criteria that included assessment of 14
vessel and parenchymal pathologies in 13 brain regions. To
validate VCING, the neuropathologists performed blinded
assessment of 114 brains from people with little or no AD
(Braak NFT stage ≤ III) or Lewy body pathology. Inter-rater
reliability analyses showed VCING to be reproducible, with
almost perfect agreement among neuropathologists (AC2
coefficient >0.8 [173]) for most scoring, apart from that of
AS and microinfarcts, which was more variable (0.4 to
≤0.8). Multivariate logistic regression determined that the
best predictive model (area under ROC curve 76 %) of cog-
nitive impairment included moderate/severe occipital lepto-
meningeal cerebral amyloid angiopathy, moderate/severe
arteriolosclerosis in occipital white matter and at least one
large infarct (i.e., over 1 cm in diameter). The various com-
binations of these three pathologies can be used to report a
low (<50 %), intermediate (50–80 %) or high (>80 %) likeli-
hood that cerebrovascular disease contributed to cognitive
impairment [174].
Fig. 5 Neuroinflammatory markers in donated human brain tissue
from older people. a Immunohistochemical labelling for the pan-
selective microglial marker Iba-1. b Activated microglia in a phagocytic
state, with amoeboid morphology, immunoreactive for lysosomal
marker CD68 (clone PGM1). c Immunoreactivity for endothelial marker
thrombomodulin (TM) in a small penetrating artery of the anterior
putamen. d Immunoreactivity for the large plasma protein fibrinogen
(FGEN) in deep subcortical white matter. Perivascular cells with astro-
cytic morphology show cellular labelling (arrows). e A localised cluster
of activated microglia (CD68+ (PGM1)), indicating a focal white matter
lesion within deep subcortical white matter. f Magnified image of E
exhibiting a small arterial vessel. Haematoxylin counterstain was used
in a–f. Scale bars represent 20 μm in images a, b and c; 100 μm in
image e, and 50 μm in images d and f
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In addition to the refinement of routine neuropatho-
logical scoring criteria, complementary methods such as
post-mortem MRI and biochemical assessment are
promising tools to investigate CVD. These should be
helpful not only to better understand the pathophysi-
ology of VCI/VaD but also to clarify the pathophysio-
logical processes that ultimately lead to characteristic
findings of in vivo imaging. The latter seems a timely
need, since current assumptions regarding the ‘causes’ of
WMH and cerebral microbleeds may not be accurate in
all cases and, hence, negatively impact on the diagnostic
accuracy of respective clinical diagnoses.
Acknowledgements
We are grateful to the individuals and their families who kindly donated
their brains for research.
Funding
KEM is currently supported by the by the Alzheimer’s Society, UK. LTG was
funded by institutional NIH grants (P50AG023501, P01AG019724 and R01
AG040311). TH has received support from the Hungarian Brain Research
Program (KTIA_13_NAP-A-II/7). Cerebral tissue for some studies in this
consensus was provided by the Newcastle Brain Tissue Resource, which is
funded in part by a grant from the UK Medical Research Council (grant
number G0400074) and by Brains for Dementia research, a joint venture
between Alzheimer’s Society and Alzheimer’s Research UK.
Authors’ contributions
Review concept and design were conceived by JA, KEM and SL. Manuscript
contributions were made by KEM, AC, JDR, LTG, AHH, TH, KJ, SL and OS. The
final manuscript was drafted by KEM and JA. Critical revisions and general
consensus were made by IA, LTG, TH, PI, KJ, JG, RNK, GGK, EK, SL, MP, RT,
DRT, DW, SBW and JA. Figures 1 and 2 were prepared by KEM, Fig. 4 by SL,
and Fig. 5 by AHH. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
2Department of Immunology, Genetics and Pathology, Uppsala University,
Uppsala, Sweden. 3Hemorrhagic Stroke Research Program, Department of
Neurology, Massachusetts General Hospital Stroke Research Center, Harvard
Medical School, Boston, MA, USA. 4Stroke Research Team, University Hospital
Lille, Lille, France. 5Departments of neurology and Pathology, University of
California, San Francisco, USA. 6Department of Pathology – LIM-22, University of
Sao Paulo Medical School, São Paulo, Brazil. 7Institute of Cardiovascular and Cell
Sciences, St George’s University of London, London, UK. 8Department of
Neuropathology, University of Debrecen, Debrecen, Hungary. 9Sheffield Institute
for Translational Neuroscience, Sheffield, UK. 10Institute of Clinical Neurobiology,
Vienna, Austria. 11Neurological Department, Peking Union Medical College
Hospital, Beijing, China. 12Institute of Neurology, Medical University of Vienna,
Vienna, Austria. 13Department of Mental Health and Psychiatry, University of
Geneva, Geneva, Switzerland. 14Clincial Neurosciences, University of Bristol, Bristol,
UK. 15Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana,
Slovenia. 16Unit of Neuropathology, Centro Hospitalar do Porto, University of
Porto, Porto, Portugal. 17Department of Neuroscience, KU-Leuven and Department
of Pathology, UZ-Leuven, Leuven, Belgium. 18Institute of Neurology, University
College London, London, UK.
Received: 28 May 2016 Accepted: 19 August 2016
References
1. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh
C, Connor DJ, Sabbagh M, et al. Circle of Willis atherosclerosis: association
with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta
Neuropathol. 2007;113(1):13–21.
2. Stary HC. Natural history and histological classification of atherosclerotic
lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20(5):1177–8.
3. Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta
Neuropathol. 2010;119(3):277–90.
4. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in
Alzheimer disease: correlation of cerebral amyloid angiopathy and
arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp
Neurol. 2003;62(12):1287–301.
5. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke.
1987;18(2):311–24.
6. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications,
and possible pathomechanisms. Acta Neuropathol. 2005;110(4):345–59.
7. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R.
‘Malignant’ middle cerebral artery territory infarction: clinical course and
prognostic signs. Arch Neurol. 1996;53(4):309–15.
8. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer
type: a pathoanatomical study. Ann Neurol. 1986;19(3):253–62.
9. Challa VR, Bell MA, Moody DM. A combined hematoxylin-eosin, alkaline
phosphatase and high-resolution microradiographic study of lacunes. Clin
Neuropathol. 1990;9(4):196–204.
10. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman
R, Warach S, Launer LJ, Van Buchem MA, Breteler MM, Microbleed Study G.
Cerebral microbleeds: a guide to detection and interpretation. Lancet
Neurol. 2009;8(2):165–74.
11. Jeong JH, Yoon SJ, Kang SJ, Choi KG, Na DL. Hypertensive pontine
microhemorrhage. Stroke. 2002;33(4):925–9.
12. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner
H, Lechner H. Pathologic correlates of incidental MRI white matter signal
hyperintensities. Neurology. 1993;43(9):1683–9.
13. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE,
Powers WJ, DeCarli C, Merino JG, Kalaria RN, et al. National Institute of
Neurological Disorders and Stroke-Canadian Stroke Network vascular
cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41.
14. Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S,
Enzinger C, Ropele S, Erkinjuntti T, et al. Heterogeneity in age-related white
matter changes. Acta Neuropathol. 2011;122(2):171–85.
15. Ferrer I. Cognitive impairment of vascular origin: neuropathology of
cognitive impairment of vascular origin. J Neurol Sci. 2010;299(1-2):139–49.
16. Jellinger KA. The pathology of “vascular dementia”: a critical update.
J Alzheimers Dis. 2008;14(1):107–23.
17. Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel
disorders contribute to the development of dementia in the elderly brain.
Exp Gerontol. 2012;47(11):816–24.
18. Korczyn AD. Mixed dementia–the most common cause of dementia. Ann N
Y Acad Sci. 2002;977:129–34.
19. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of
Alzheimer disease-associated neurofibrillary pathology using paraffin
sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404.
20. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson
DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-
Alzheimer’s Association guidelines for the neuropathologic assessment of
Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13.
21. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS,
Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic
assessment of Alzheimer’s disease. Neurology. 1991;41(4):479–86.
22. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the
human brain and its relevance for the development of AD. Neurology.
2002;58(12):1791–800.
23. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-
a critical update. Front Aging Neurosci. 2013;5:17.
24. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of
different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for
the diagnosis of vascular dementia. National Institute of Neurological
Disorders and Stroke-Association Internationale pour la Recherche et
l’Enseignement en Neurosciences. Stroke. 2000;31(12):2952–7.
25. Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of
dementia: design, methods and areas of investigation–a systematic review.
BMC Neurol. 2006;6:2.
26. Grinberg LT, Nitrini R, Suemoto CK, Lucena Ferretti-Rebustini RE, Leite RE,
Farfel JM, Santos E, Andrade MP, Alho AT, Lima Mdo C, et al. Prevalence of
McAleese et al. BMC Medicine  (2016) 14:129 Page 12 of 16
dementia subtypes in a developing country: a clinicopathological study.
Clinics (Sao Paulo). 2013;68(8):1140–5.
27. Jellinger KA, Attems J. Prevalence and pathology of vascular dementia in
the oldest-old. J Alzheimers Dis. 2010;21(4):1283–93.
28. Grinberg LT, Heinsen H. Toward a pathological definition of vascular
dementia. J Neurol Sci. 2010;299(1-2):136–8.
29. Alafuzoff I, Gelpi E, Al-Sarraj S, Arzberger T, Attems J, Bodi I, Bogdanovic
N, Budka H, Bugiani O, Englund E, et al. The need to unify
neuropathological assessments of vascular alterations in the ageing
brain: Multicentre survey by the BrainNet Europe consortium. Exp
Gerontol. 2012;47(11):825–33.
30. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol. 1991;82(4):239–59.
31. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging
of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging.
2003;24(2):197–211.
32. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings
J, Duda JE, Lippa C, Perry EK, et al. Diagnosis and management of dementia
with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;
65(12):1863–72.
33. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW,
Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on
Aging-Alzheimer’s Association guidelines for the neuropathologic
assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol.
2012;123(1):1–11.
34. Deramecourt V, Slade JY, Oakley AE, Perry RH, Ince PG, Maurage CA, Kalaria
RN. Staging and natural history of cerebrovascular pathology in dementia.
Neurology. 2012;78(14):1043–50.
35. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards
defining the neuropathological substrates of vascular dementia. J Neurol
Sci. 2004;226(1-2):75–80.
36. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH,
Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia:
diagnostic criteria for research studies. Report of the NINDS-AIREN
International Workshop. Neurology. 1993;43(2):250–60.
37. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old:
an autopsy study. Acta Neuropathol. 2010;119(4):421–33.
38. Seo SW, Hwa Lee B, Kim EJ, Chin J, Sun Cho Y, Yoon U, Na DL. Clinical
significance of microbleeds in subcortical vascular dementia. Stroke.
2007;38(6):1949–51.
39. Barker R, Ashby EL, Wellington D, Barrow VM, Palmer JC, Kehoe PG, Esiri
MM, Love S. Pathophysiology of white matter perfusion in Alzheimer’s
disease and vascular dementia. Brain. 2014;137(Pt 5):1524–32.
40. Attems J, Jellinger KA. The overlap between vascular disease and
Alzheimer’s disease–lessons from pathology. BMC Med. 2014;12:206.
41. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer
LJ, Laurent S, Lopez OL, Nyenhuis D, et al. Vascular contributions to
cognitive impairment and dementia: a statement for healthcare
professionals from the american heart association/american stroke
association. Stroke. 2011;42(9):2672–713.
42. Trattnig S, Bogner W, Gruber S, Szomolanyi P, Juras V, Robinson S, Zbyn S,
Haneder S. Clinical applications at ultrahigh field (7T). Where does it make
the difference? NMR Biomed. 2015;29(9):1316–34.
43. van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, Spliet WG, Hendrikse J, Luijten
PR, Biessels GJ. In vivo detection of cerebral cortical microinfarcts with high-
resolution 7T MRI. J Cereb Blood Flow Metab. 2013;33(3):322–9.
44. van Veluw SJ, Zwanenburg JJ, Rozemuller AJ, Luijten PR, Spliet WG, Biessels
GJ. The spectrum of MR detectable cortical microinfarcts: a classification
study with 7-tesla postmortem MRI and histopathology. J Cereb Blood Flow
Metab. 2015;35(4):676–83.
45. De Reuck J, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D,
Defebvre L, Moreau C, Caparros-Lefebvre D, Bordet R, et al. Post-mortem 7.
0-tesla magnetic resonance study of cortical microinfarcts in
neurodegenerative diseases and vascular dementia with neuropathological
correlates. J Neurol Sci. 2014;346(1-2):85–9.
46. Sachdev P, Kalaria R, O’Brien J, Skoog I, Alladi S, Black SE, Blacker D, Blazer DG,
Chen C, Chui H, et al. Diagnostic criteria for vascular cognitive disorders: a
VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–18.
47. Bacchetta JP, Kovari E, Merlo M, Canuto A, Herrmann FR, Bouras C, Gold G,
Hof PR, Giannakopoulos P. Validation of clinical criteria for possible vascular
dementia in the oldest-old. Neurobiol Aging. 2007;28(4):579–85.
48. Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, Edland SD,
Rocca WA. Vascular dementia in a population-based autopsy study. Arch
Neurol. 2003;60(4):569–75.
49. Chui HC, Ramirez-Gomez L. Clinical and imaging features of mixed
Alzheimer and vascular pathologies. Alzheimers Res Ther. 2015;7(1):21.
50. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, Jagust WJ,
Chui HC. Profiles of neuropsychological impairment in autopsy-defined
Alzheimer’s disease and cerebrovascular disease. Brain. 2007;130(Pt 3):731–9.
51. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M,
Pontecorvo M, Baker SL, Jagust WJ. Amyloid PET imaging in Alzheimer’s
disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging.
2014;41(7):1398–407.
52. Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske GM, Kantarci K,
Raman MR, Machulda MM, Mielke MM, Lowe VJ, et al. Vascular and amyloid
pathologies are independent predictors of cognitive decline in normal
elderly. Brain. 2015;138(Pt 3):761–71.
53. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR.
Brain infarction and the clinical expression of Alzheimer disease. The Nun
Study. JAMA. 1997;277(10):813–7.
54. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs
RC, Peterson BL, Pieper CF. Cerebral infarcts in patients with autopsy-proven
Alzheimer’s disease: CERAD, part XVIII. Consortium to Establish a Registry for
Alzheimer’s Disease. Neurology. 1998;51(1):159–62.
55. Petrovitch H, Ross GW, Steinhorn SC, Abbott RD, Markesbery W, Davis D,
Nelson J, Hardman J, Masaki K, Vogt MR, et al. AD lesions and infarcts in
demented and non-demented Japanese-American men. Ann Neurol.
2005;57(1):98–103.
56. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of
neuropathology to cognition in persons without cognitive impairment. Ann
Neurol. 2012;72(4):599–609.
57. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C,
Aronson M, Wolfson L. Clinico-pathologic studies in dementia:
nondemented subjects with pathologically confirmed Alzheimer’s disease.
Neurology. 1988;38(11):1682–7.
58. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer
neuropathologic alterations in aged cognitively normal subjects. J
Neuropathol Exp Neurol. 1999;58(4):376–88.
59. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH,
Aronson MK. Identification of normal and pathological aging in
prospectively studied nondemented elderly humans. Neurobiol Aging.
1992;13(1):179–89.
60. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The
neuropathology of older persons with and without dementia from
community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691–701.
61. Stephan BC, Matthews FE, Ma B, Muniz G, Hunter S, Davis D, McKeith IG,
Foster G, Ince PG, Brayne C. Alzheimer and vascular neuropathological
changes associated with different cognitive States in a non-demented
sample. J Alzheimers Dis. 2012;29(2):309–18.
62. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC,
Wilson RS. Neuropathology of older persons without cognitive impairment
from two community-based studies. Neurology. 2006;66(12):1837–44.
63. Buchman AS, Leurgans SE, Nag S, Bennett DA, Schneider JA.
Cerebrovascular disease pathology and parkinsonian signs in old age.
Stroke. 2011;42(11):3183–9.
64. White L. Brain lesions at autopsy in older Japanese-American men as related to
cognitive impairment and dementia in the final years of life: a summary report
from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18(3):713–25.
65. Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS,
Jack CR, Kaye J, Lim K, Larson EB, et al. Ecology of the aging human brain.
Arch Neurol. 2011;68(8):1049–56.
66. Jellinger KA, Attems J. Neuropathology and general autopsy findings in
nondemented aged subjects. Clin Neuropathol. 2012;31(2):87–98.
67. Goulding JM, Signorini DF, Chatterjee S, Nicoll JA, Stewart J, Morris R,
Lammie GA. Inverse relation between Braak stage and cerebrovascular
pathology in Alzheimer predominant dementia. J Neurol Neurosurg
Psychiatry. 1999;67(5):654–7.
68. Jellinger K. Inverse relation between Braak stage and cerebrovascular
pathology in Alzheimer predominant dementia. J Neurol Neurosurg
Psychiatry. 2000;68(6):799–800.
69. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M,
Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular
McAleese et al. BMC Medicine  (2016) 14:129 Page 13 of 16
disease in autopsy confirmed neurodegenerative disease cases in the
National Alzheimer’s Coordinating Centre. Brain. 2013;136(Pt 9):2697–706.
70. Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies. A
postmortem study. J Neural Transm. 2003;110(7):771–8.
71. Ghebremedhin E, Rosenberger A, Rub U, Vuksic M, Berhe T, Bickeboller H,
de Vos RA, Thal DR, Deller T. Inverse relationship between cerebrovascular
lesions and severity of lewy body pathology in patients with lewy body
diseases. J Neuropathol Exp Neurol. 2010;69(5):442–8.
72. Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J,
Arzberger T. Frontotemporal lobar degeneration FTLD-tau: preclinical
lesions, vascular, and Alzheimer-related co-pathologies. J Neural Transm
(Vienna). 2015;122(7):1007–18.
73. Ince PG. Pathological correlates of late-onset dementia in a multicentre,
community-based population in England and Wales. Neuropathology
Group of the Medical Research Council Cognitive Function and Ageing
Study (MRC CFAS). Lancet. 2001;357(9251):169–75.
74. Smallwood A, Oulhaj A, Joachim C, Christie S, Sloan C, Smith AD, Esiri M.
Cerebral subcortical small vessel disease and its relation to cognition in
elderly subjects: a pathological study in the Oxford Project to Investigate
Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol.
2012;38(4):337–43.
75. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G,
Filippi M. White matter damage in Alzheimer’s disease assessed in vivo
using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg
Psychiatry. 2002;72(6):742–6.
76. McAleese KE, Firbank M, Hunter D, Sun L, Hall R, Neal JW, Mann DM, Esiri M,
Jellinger KA, O’Brien JT, et al. Magnetic resonance imaging of fixed post
mortem brains reliably reflects subcortical vascular pathology of frontal,
parietal and occipital white matter. Neuropathol Appl Neurobiol. 2013;39(5):
485–97.
77. Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinisto L,
Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN. Frontal lobe white matter
hyperintensities and neurofibrillary pathology in the oldest old. Neurology.
2010;75(23):2071–8.
78. Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H,
Howieson DB, Wild K, Silbert LC. Neuropathologic basis of white matter
hyperintensity accumulation with advanced age. Neurology. 2013;81(11):
977–83.
79. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria
RN, Forster G, Esteves F, Wharton SB, et al. White matter lesions in an
unselected cohort of the elderly: molecular pathology suggests origin from
chronic hypoperfusion injury. Stroke. 2006;37(6):1391–8.
80. Lee DY, Fletcher E, Martinez O, Ortega M, Zozulya N, Kim J, Tran J,
Buonocore M, Carmichael O, DeCarli C. Regional pattern of white matter
microstructural changes in normal aging, MCI, and AD. Neurology. 2009;
73(21):1722–8.
81. Lee DY, Fletcher E, Martinez O, Zozulya N, Kim J, Tran J, Buonocore M,
Carmichael O, DeCarli C. Vascular and degenerative processes differentially
affect regional interhemispheric connections in normal aging, mild
cognitive impairment, and Alzheimer disease. Stroke. 2010;41(8):1791–7.
82. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas DM, Reed
BR, DeCarli CS. Extent and distribution of white matter hyperintensities in
normal aging, MCI, and AD. Neurology. 2006;67(12):2192–8.
83. Coleman M. Axon degeneration mechanisms: commonality amid diversity.
Nat Rev Neurosci. 2005;6(11):889–98.
84. Leys D, Pruvo JP, Parent M, Vermersch P, Soetaert G, Steinling M, Delacourte
A, Defossez A, Rapoport A, Clarisse J, et al. Could Wallerian degeneration
contribute to “leuko-araiosis” in subjects free of any vascular disorder? J
Neurol Neurosurg Psychiatry. 1991;54(1):46–50.
85. Agosta F, Pievani M, Sala S, Geroldi C, Galluzzi S, Frisoni GB, Filippi M. White
matter damage in Alzheimer disease and its relationship to gray matter
atrophy. Radiology. 2011;258(3):853–63.
86. Bosch B, Arenaza-Urquijo EM, Rami L, Sala-Llonch R, Junque C,
Sole-Padulles C, Pena-Gomez C, Bargallo N, Molinuevo JL, Bartres-Faz D.
Multiple DTI index analysis in normal aging, amnestic MCI and AD.
Relationship with neuropsychological performance. Neurobiol Aging.
2012;33(1):61–74.
87. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M,
Beverley JR, Taylor JP, Thomas AJ, O’Brien JT, et al. Cortical tau load is
associated with white matter hyperintensities. Acta Neuropathol
Commun. 2015;3:60.
88. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, Ellis WG,
Zarow C, Mungas D, Reed BR, et al. Neuropathological basis of magnetic
resonance images in aging and dementia. Ann Neurol. 2008;63(1):72–80.
89. Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM.
Alzheimer’s Disease Neuroimaging I: The effect of white matter
hyperintensities on neurodegeneration in mild cognitive impairment.
Alzheimers Dement. 2015;11(12):1510–9.
90. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;
28(3):652–9.
91. Englund E. Neuropathology of white matter changes in Alzheimer’s disease
and vascular dementia. Dement Geriatr Cogn Disord. 1998;9 Suppl 1:6–12.
92. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R,
Lindley RI, O’Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging
standards for research into small vessel disease and its contribution to
ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.
93. Chen A, Akinyemi RO, Hase Y, Firbank MJ, Ndung’u MN, Foster V, Craggs LJ,
Washida K, Okamoto Y, Thomas AJ, et al. Frontal white matter
hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing
and post-stroke dementia. Brain. 2016;139(Pt 1):242–58.
94. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain
microbleeds: systematic review, subgroup analyses and standards for study
design and reporting. Brain. 2007;130(Pt 8):1988–2003.
95. Werring DJ, Coward LJ, Losseff NA, Jager HR, Brown MM. Cerebral
microbleeds are common in ischemic stroke but rare in TIA. Neurology.
2005;65(12):1914–8.
96. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-
Hyslop P, Rogaeva E, Black SE. Microbleed topography, leukoaraiosis, and
cognition in probable Alzheimer disease from the Sunnybrook dementia
study. Arch Neurol. 2008;65(6):790–5.
97. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease:
innocent observation or key player? Brain. 2011;134(Pt 2):335–44.
98. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P.
Prevalence and severity of microbleeds in a memory clinic setting.
Neurology. 2006;66(9):1356–60.
99. Werring D. Cerebral Microbleeds: Pathophysiology to Clinical Practice.
Cambridge: Cambridge University Press; 2011.
100. Charidimou A, Werring DJ. Cerebral microbleeds: detection, mechanisms
and clinical challenges. Future Neurol. 2011;6(5):587–611.
101. Kakar P, Charidimou A, Werring DJ. Cerebral microbleeds: a new
dilemma in stroke medicine. JRSM Cardiovasc Dis. 2012;1(8):
2048004012474754.
102. Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrombotic therapy
safe to administer? Stroke. 2014;45(9):2811–7.
103. Soo YO, Yang SR, Lam WW, Wong A, Fan YH, Leung HH, Chan AY,
Leung C, Leung TW, Wong LK. Risk vs benefit of anti-thrombotic
therapy in ischaemic stroke patients with cerebral microbleeds.
J Neurol. 2008;255(11):1679–86.
104. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL,
Edinburgh Stroke Study G, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi
T, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral
hemorrhage: a systematic review of published and unpublished studies.
Stroke. 2010;41(6):1222–8.
105. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and
recurrent stroke risk: systematic review and meta-analysis of prospective
ischemic stroke and transient ischemic attack cohorts. Stroke. 2013;44(4):
995–1001.
106. Charidimou A, Shakeshaft C, Werring DJ. Cerebral microbleeds on magnetic
resonance imaging and anticoagulant-associated intracerebral hemorrhage
risk. Front Neurol. 2012;3:133.
107. Lei C, Lin S, Tao W, Hao Z, Liu M, Wu B. Association between cerebral
microbleeds and cognitive function: a systematic review. J Neurol
Neurosurg Psychiatry. 2013;84(6):693–7.
108. Charidimou A, Jager HR, Werring DJ. Cerebral microbleed detection and
mapping: Principles, methodological aspects and rationale in vascular
dementia. Exp Gerontol. 2012;47(11):843–52.
109. Fisher M. Cerebral microbleeds: where are we now? Neurology. 2014;83(15):
1304–5.
110. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R, Hartung HP.
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR
images in patients with spontaneous intracerebral hemorrhage: evidence of
microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999;20(4):637–42.
McAleese et al. BMC Medicine  (2016) 14:129 Page 14 of 16
111. Tatsumi S, Shinohara M, Yamamoto T. Direct comparison of histology of
microbleeds with postmortem MR images. A case report. Cerebrovasc Dis.
2008;26(2):142–6.
112. Schrag M, McAuley G, Pomakian J, Jiffry A, Tung S, Mueller C, Vinters HV,
Haacke EM, Holshouser B, Kido D, et al. Correlation of hypointensities in
susceptibility-weighted images to tissue histology in dementia patients with
cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol.
2010;119(3):291–302.
113. Boulanger JM, Coutts SB, Eliasziw M, Gagnon AJ, Simon JE, Subramaniam S,
Sohn CH, Scott J, Demchuk AM, Group VS. Cerebral microhemorrhages predict
new disabling or fatal strokes in patients with acute ischemic stroke or
transient ischemic attack. Stroke. 2006;37(3):911–4.
114. Thijs V, Lemmens R, Schoofs C, Gorner A, Van Damme P, Schrooten M,
Demaerel P. Microbleeds and the risk of recurrent stroke. Stroke. 2010;41(9):
2005–9.
115. Lim JS, Hong KS, Kim GM, Bang OY, Bae HJ, Kwon HM, Park JM, Lee SH, Rha
JH, Koo J, et al. Cerebral microbleeds and early recurrent stroke after
transient ischemic attack: results from the Korean Transient Ischemic Attack
Expression Registry. JAMA Neurol. 2015;72(3):301–8.
116. Fluri F, Jax F, Amort M, Wetzel SG, Lyrer PA, Katan M, Hatz F, Engelter ST.
Significance of microbleeds in patients with transient ischaemic attack. Eur J
Neurol. 2012;19(3):522–4.
117. Fisher M, Vasilevko V, Cribbs DH. Mixed cerebrovascular disease and the
future of stroke prevention. Transl Stroke Res. 2012;3 Suppl 1:39–51.
118. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological
correlation of neuroimaging. Cerebrovasc Dis. 2011;32(6):528–34.
119. Wardlaw JM. Post-mortem MR brain imaging comparison with macro- and
histopathology: useful, important and underused. Cerebrovasc Dis.
2011;31(5):518–9.
120. Charidimou A, Werring DJ. Letter by Charidimou and Werring regarding
article, “Cerebral microbleeds in the elderly”. Stroke. 2011;42(4):e368.
121. De Reuck J, Auger F, Cordonnier C, Deramecourt V, Durieux N, Pasquier F,
Bordet R, Maurage CA, Leys D. Comparison of 7.0-T T(2)*-Magnetic
Resonance Imaging of Cerebral Bleeds in Post-Mortem Brain Sections of
Alzheimer Patients with Their Neuropathological Correlates. Cerebrovasc
Dis. 2011;31(5):511–7.
122. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM,
Scheltens P, Geurts JJ. Heterogeneity of small vessel disease: a systematic
review of MRI and histopathology correlations. J Neurol Neurosurg
Psychiatry. 2011;82(2):126–35.
123. Janaway BM, Simpson JE, Hoggard N, Highley JR, Forster G, Drew D, Gebril
OH, Matthews FE, Brayne C, Wharton SB, et al. Brain haemosiderin in older
people: pathological evidence for an ischaemic origin of magnetic
resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol.
2014;40(3):258–69.
124. Grutzendler J, Murikinati S, Hiner B, Ji L, Lam CK, Yoo T, Gupta S, Hafler BP,
Adelman RA, Yuan P, et al. Angiophagy prevents early embolus washout
but recanalizes microvessels through embolus extravasation. Sci Transl Med.
2014;6(226):226ra231.
125. Tanskanen M, Makela M, Myllykangas L, Rastas S, Sulkava R, Paetau A.
Intracerebral hemorrhage in the oldest old: a population-based study
(vantaa 85+). Front Neurol. 2012;3:103.
126. Rosand J, Muzikansky A, Kumar A, Wisco JJ, Smith EE, Betensky RA,
Greenberg SM. Spatial clustering of hemorrhages in probable cerebral
amyloid angiopathy. Ann Neurol. 2005;58(3):459–62.
127. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der
Lugt A, Breteler MM. Prevalence and risk factors of cerebral
microbleeds: an update of the Rotterdam scan study. Stroke. 2010;
41(10 Suppl):S103–106.
128. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ,
Hofman A, Krestin GP, Breteler MM. Prevalence and risk factors of cerebral
microbleeds: the Rotterdam Scan Study. Neurology. 2008;70(14):1208–14.
129. O’Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D,
Greenberg SM. Apolipoprotein E genotype and the risk of recurrent lobar
intracerebral hemorrhage. N Engl J Med. 2000;342(4):240–5.
130. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar
A, Neal KL, Betensky RA, Frosch MP, et al. Spatial relation between
microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol.
2010;68(4):545–8.
131. De Reuck J, Auger F, Durieux N, Deramecourt V, Cordonnier C, Pasquier F,
Maurage CA, Leys D, Bordet R. Topography of Cortical Microbleeds in
Alzheimer’s Disease with and without Cerebral Amyloid Angiopathy: A Post-
Mortem 7.0-Tesla MRI Study. Aging Dis. 2015;6(6):437–43.
132. Kovari E, Charidimou A, Herrmann FR, Giannakopoulos P, Bouras C, Gold G.
No neuropathological evidence for a direct topographical relation between
microbleeds and cerebral amyloid angiopathy. Acta Neuropathol Commun.
2015;3(1):49.
133. Caplan LR. Microbleeds. Circulation. 2015;132(6):479–80.
134. Awad IA, Johnson PC, Spetzler RF, Hodak JA. Incidental subcortical lesions
identified on magnetic resonance imaging in the elderly. II. Postmortem
pathological correlations. Stroke. 1986;17(6):1090–7.
135. Pfefferbaum A, Sullivan EV, Adalsteinsson E, Garrick T, Harper C.
Postmortem MR imaging of formalin-fixed human brain. Neuroimage.
2004;21(4):1585–95.
136. Schmierer K, Wheeler-Kingshott CA, Tozer DJ, Boulby PA, Parkes HG, Yousry
TA, Scaravilli F, Barker GJ, Tofts PS, Miller DH. Quantitative magnetic
resonance of postmortem multiple sclerosis brain before and after fixation.
Magn Reson Med. 2008;59(2):268–77.
137. Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction
from enlarged Virchow-Robin spaces: a magnetic resonance imaging and
pathological study. J Neurol. 1998;245(2):116–22.
138. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W.
Histopathologic correlates of white matter changes on MRI in Alzheimer’s
disease and normal aging. Neurology. 1995;45(5):883–8.
139. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter
hyperintensities. Neurology. 2008;71(11):804–11.
140. Murray ME, Vemuri P, Preboske GM, Murphy MC, Schweitzer KJ, Parisi JE,
Jack Jr CR, Dickson DW. A quantitative postmortem MRI design sensitive to
white matter hyperintensity differences and their relationship with
underlying pathology. J Neuropathol Exp Neurol. 2012;71(12):1113–22.
141. De Reuck JL, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D,
Defebvre L, Moreau C, Capparos-Lefebvre D, Pasquier F, et al. The
significance of cortical cerebellar microbleeds and microinfarcts in
neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla
magnetic resonance study with neuropathological correlates. Cerebrovasc
Dis. 2015;39(2):138–43.
142. Fernando MS, O’Brien JT, Perry RH, English P, Forster G, McMeekin W, Slade
JY, Golkhar A, Matthews FE, Barber R, et al. Comparison of the pathology of
cerebral white matter with post-mortem magnetic resonance imaging (MRI)
in the elderly brain. Neuropathol Appl Neurobiol. 2004;30(4):385–95.
143. Grinberg LT, Amaro Junior E, da Silva AV, da Silva RE, Sato JR, dos Santos
DD, de Paula PS, de Lucena Ferretti RE, Paraizo Leite RE, Pasqualucci CA,
et al. Improved detection of incipient vascular changes by a biotechnological
platform combining post mortem MRI in situ with neuropathology. J Neurol
Sci. 2009;283(1-2):2–8.
144. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin
A, Ader H, Leys D, Pantoni L, et al. A new rating scale for age-related white
matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318–22.
145. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts:
the invisible lesions. Lancet Neurol. 2012;11(3):272–82.
146. Csiba L, Farkas S, Kollar J, Berenyi E, Nagy K, Bereczki D. Visualization of the
ischemic core on native human brain slices by potassium staining method.
J Neurosci Methods. 2010;192(1):17–21.
147. Mies G, Kloiber O, Drewes LR, Hossmann KA. Cerebral blood flow and
regional potassium distribution during focal ischemia of gerbil brain. Ann
Neurol. 1984;16(2):232–7.
148. Palkovits M. Isolated removal of hypothalamic or other brain nuclei of the
rat. Brain Res. 1973;59:449–50.
149. Miners JS, Palmer JC, Love S. Pathophysiology of Hypoperfusion of the
Precuneus in Early Alzheimer’s Disease. Brain Pathol. 2016;26(4):533–41.
150. Barker R, Wellington D, Esiri MM, Love S. Assessing white matter ischemic
damage in dementia patients by measurement of myelin proteins. J Cereb
Blood Flow Metab. 2013;33(7):1050–7.
151. Thomas T, Miners S, Love S. Post-mortem assessment of hypoperfusion of
cerebral cortex in Alzheimer’s disease and vascular dementia. Brain.
2015;138(Pt 4):1059–69.
152. Palmer JC, Baig S, Kehoe PG, Love S. Endothelin-converting enzyme-2 is
increased in Alzheimer’s disease and up-regulated by Aβ. Am J Pathol.
2009;175(1):262–70.
153. Palmer JC, Barker R, Kehoe PG, Love S. Endothelin-1 is elevated in
Alzheimer’s disease and upregulated by amyloid-β. J Alzheimers Dis. 2012;
29(4):853–61.
McAleese et al. BMC Medicine  (2016) 14:129 Page 15 of 16
154. Palmer JC, Tayler HM, Love S. Endothelin-converting enzyme-1 activity,
endothelin-1 production, and free radical-dependent vasoconstriction in
Alzheimer’s disease. J Alzheimers Dis. 2013;36(3):577–87.
155. Miners S, Moulding H, de Silva R, Love S. Reduced vascular endothelial
growth factor and capillary density in the occipital cortex in dementia with
Lewy bodies. Brain Pathol. 2014;24(4):334–43.
156. Hainsworth AH, Oommen AT, Bridges LR. Endothelial cells and human
cerebral small vessel disease. Brain Pathol. 2015;25(1):44–50.
157. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL,
Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation
in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
158. Streit WJ, Xue QS, Tischer J, Bechmann I. Microglial pathology. Acta
Neuropathol Commun. 2014;2:142.
159. Hassan A, Hunt BJ, O’Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM,
Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar
infarction and ischaemic leukoaraiosis. Brain. 2003;126(Pt 2):424–32.
160. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of
endothelial and hemostatic activation and progression of cerebral white
matter hyperintensities: longitudinal results of the Austrian Stroke
Prevention Study. Stroke. 2005;36(7):1410–4.
161. Fornage M, Chiang YA, O’Meara ES, Psaty BM, Reiner AP, Siscovick DS, Tracy
RP, Longstreth Jr WT. Biomarkers of Inflammation and MRI-Defined Small
Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke. 2008;
39(7):1952–9.
162. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, Rouhl RP, Staals J, Spronk
HM, van Oerle R, van Raak EP, Lodder J, ten Cate H, et al. Endothelial
activation in lacunar stroke subtypes. Stroke. 2010;41(8):1617–22.
163. Stevenson SF, Doubal FN, Shuler K, Wardlaw JM. A systematic review of
dynamic cerebral and peripheral endothelial function in lacunar stroke
versus controls. Stroke. 2010;41(6):e434–442.
164. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, Markus HS,
Esiri MM, Hainsworth AH. Neuropathologic evidence of endothelial changes
in cerebral small vessel disease. Neurology. 2012;78(3):167–74.
165. Mulugeta E, Molina-Holgado F, Elliott MS, Hortobagyi T, Perry R, Kalaria RN,
Ballard CG, Francis PT. Inflammatory mediators in the frontal lobe of
patients with mixed and vascular dementia. Dement Geriatr Cogn Disord.
2008;25(3):278–86.
166. Tomimoto H, Akiguchi I, Suenaga T, Nishimura M, Wakita H, Nakamura S,
Kimura J. Alterations of the blood-brain barrier and glial cells in white-
matter lesions in cerebrovascular and Alzheimer’s disease patients. Stroke.
1996;27(11):2069–74.
167. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU,
Ghebremedhin E, Thal DR. Cerebral small vessel disease-induced
apolipoprotein E leakage is associated with Alzheimer disease and the
accumulation of amyloid beta-protein in perivascular astrocytes.
J Neuropathol Exp Neurol. 2008;67(9):842–56.
168. Viggars AP, Wharton SB, Simpson JE, Matthews FE, Brayne C, Savva GM,
Garwood C, Drew D, Shaw PJ, Ince PG. Alterations in the blood brain barrier
in ageing cerebral cortex in relationship to Alzheimer-type pathology: a
study in the MRC-CFAS population neuropathology cohort. Neurosci Lett.
2011;505(1):25–30.
169. Bridges LR, Andoh J, Lawrence AJ, Khoong CH, Poon WW, Esiri MM, Markus
HS, Hainsworth AH. Blood-brain barrier dysfunction and cerebral small
vessel disease (arteriolosclerosis) in brains of older people. J Neuropathol
Exp Neurol. 2014;73(11):1026–33.
170. Simpson JE, Fernando MS, Clark L, Ince PG, Matthews F, Forster G, O’Brien
JT, Barber R, Kalaria RN, Brayne C, et al. White matter lesions in an
unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte
precursor cell responses. Neuropathol Appl Neurobiol. 2007;33(4):410–9.
171. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H. Alterations in
glia and axons in the brains of Binswanger’s disease patients. Stroke.
1997;28(7):1423–9.
172. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci.
2012;322(1-2):2–10.
173. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics. 1977;33(1):159–74.
174. Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN, King A,
Lammie GA, Mann D, Neal JW, et al. Cognitive Impairment Neuropathology
Guidelines (VCING)- a multi-centre study of the contribution of
cerebrovascular pathology to cognitive impairment. Brain. 2016. In Press.
175. Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer’s
disease. Acta Neuropathol. 2016;131(5):645–58.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
McAleese et al. BMC Medicine  (2016) 14:129 Page 16 of 16
